Modulation of TNFα, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors

V. P. Mane, G. Toietta, W. M. McCormack, I. Conde, C. Clarke, D. Palmer, M. J. Finegold, L. Pastore, P. Ng, J. Lopez, Brendan Lee

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Understanding the determinants of the host innate immune response to systemic administration of adenoviral (Ad) vectors is critical for clinical gene therapy. Acute toxicity occurs within minutes to hours after vector administration and is characterized by activation of innate immune responses. Our data indicate that in mice, indicators of vector toxicity include elevations of cytokine levels, liver transaminase levels and thrombocytopenia. To discern potential targets for blunting this host response, we evaluated genetic factors in the host response to systemically administered first-generation Ad vectors (FGV) and helper-dependent Ad vectors (HDV) containing β-galactosidase expression cassettes. A preliminary screen for modulation of vector-induced thrombocytopenia revealed no role for interferon-γ, mast cells or perforin. However, vector-induced thrombocytopenia and interleukin 6 (IL-6) expression are less evident in tumor necrosis factor alpha (TNFα)-deficient mice. Moreover, we also demonstrated that TNFα blockade via antibody or huTNFR:Fc pretreatment attenuates both thrombocytopenia (>40% increase in platelet count) and IL-6 expression (>80% reduction) without affecting interleukin 12, liver enzymes, hematological indices or vector transduction in a murine model. Our data indicate that the use of HDV, in combination with clinically approved TNFα immunomodulation, may represent an approach for improving the therapeutic index of Ad gene therapy for human clinical trials.

Original languageEnglish
Pages (from-to)1272-1280
Number of pages9
JournalGene Therapy
Volume13
Issue number17
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Thrombocytopenia
Tumor Necrosis Factor-alpha
Innate Immunity
Genetic Therapy
Interleukin-6
Galactosidases
Perforin
Immunomodulation
Liver
Interleukin-12
Transaminases
Platelet Count
Mast Cells
Interferons
Clinical Trials
Cytokines
Antibodies
Enzymes
Therapeutics

Keywords

  • Enbrel
  • Helper-dependent
  • Innate immune response
  • Thrombocytopenia
  • TNFalpha
  • Toxicity

ASJC Scopus subject areas

  • Genetics

Cite this

Modulation of TNFα, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors. / Mane, V. P.; Toietta, G.; McCormack, W. M.; Conde, I.; Clarke, C.; Palmer, D.; Finegold, M. J.; Pastore, L.; Ng, P.; Lopez, J.; Lee, Brendan.

In: Gene Therapy, Vol. 13, No. 17, 09.2006, p. 1272-1280.

Research output: Contribution to journalArticle

Mane, VP, Toietta, G, McCormack, WM, Conde, I, Clarke, C, Palmer, D, Finegold, MJ, Pastore, L, Ng, P, Lopez, J & Lee, B 2006, 'Modulation of TNFα, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors', Gene Therapy, vol. 13, no. 17, pp. 1272-1280. https://doi.org/10.1038/sj.gt.3302792
Mane, V. P. ; Toietta, G. ; McCormack, W. M. ; Conde, I. ; Clarke, C. ; Palmer, D. ; Finegold, M. J. ; Pastore, L. ; Ng, P. ; Lopez, J. ; Lee, Brendan. / Modulation of TNFα, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors. In: Gene Therapy. 2006 ; Vol. 13, No. 17. pp. 1272-1280.
@article{b1aef44339ff4353ba0313ad9b7d84aa,
title = "Modulation of TNFα, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors",
abstract = "Understanding the determinants of the host innate immune response to systemic administration of adenoviral (Ad) vectors is critical for clinical gene therapy. Acute toxicity occurs within minutes to hours after vector administration and is characterized by activation of innate immune responses. Our data indicate that in mice, indicators of vector toxicity include elevations of cytokine levels, liver transaminase levels and thrombocytopenia. To discern potential targets for blunting this host response, we evaluated genetic factors in the host response to systemically administered first-generation Ad vectors (FGV) and helper-dependent Ad vectors (HDV) containing β-galactosidase expression cassettes. A preliminary screen for modulation of vector-induced thrombocytopenia revealed no role for interferon-γ, mast cells or perforin. However, vector-induced thrombocytopenia and interleukin 6 (IL-6) expression are less evident in tumor necrosis factor alpha (TNFα)-deficient mice. Moreover, we also demonstrated that TNFα blockade via antibody or huTNFR:Fc pretreatment attenuates both thrombocytopenia (>40{\%} increase in platelet count) and IL-6 expression (>80{\%} reduction) without affecting interleukin 12, liver enzymes, hematological indices or vector transduction in a murine model. Our data indicate that the use of HDV, in combination with clinically approved TNFα immunomodulation, may represent an approach for improving the therapeutic index of Ad gene therapy for human clinical trials.",
keywords = "Enbrel, Helper-dependent, Innate immune response, Thrombocytopenia, TNFalpha, Toxicity",
author = "Mane, {V. P.} and G. Toietta and McCormack, {W. M.} and I. Conde and C. Clarke and D. Palmer and Finegold, {M. J.} and L. Pastore and P. Ng and J. Lopez and Brendan Lee",
year = "2006",
month = "9",
doi = "10.1038/sj.gt.3302792",
language = "English",
volume = "13",
pages = "1272--1280",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "17",

}

TY - JOUR

T1 - Modulation of TNFα, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors

AU - Mane, V. P.

AU - Toietta, G.

AU - McCormack, W. M.

AU - Conde, I.

AU - Clarke, C.

AU - Palmer, D.

AU - Finegold, M. J.

AU - Pastore, L.

AU - Ng, P.

AU - Lopez, J.

AU - Lee, Brendan

PY - 2006/9

Y1 - 2006/9

N2 - Understanding the determinants of the host innate immune response to systemic administration of adenoviral (Ad) vectors is critical for clinical gene therapy. Acute toxicity occurs within minutes to hours after vector administration and is characterized by activation of innate immune responses. Our data indicate that in mice, indicators of vector toxicity include elevations of cytokine levels, liver transaminase levels and thrombocytopenia. To discern potential targets for blunting this host response, we evaluated genetic factors in the host response to systemically administered first-generation Ad vectors (FGV) and helper-dependent Ad vectors (HDV) containing β-galactosidase expression cassettes. A preliminary screen for modulation of vector-induced thrombocytopenia revealed no role for interferon-γ, mast cells or perforin. However, vector-induced thrombocytopenia and interleukin 6 (IL-6) expression are less evident in tumor necrosis factor alpha (TNFα)-deficient mice. Moreover, we also demonstrated that TNFα blockade via antibody or huTNFR:Fc pretreatment attenuates both thrombocytopenia (>40% increase in platelet count) and IL-6 expression (>80% reduction) without affecting interleukin 12, liver enzymes, hematological indices or vector transduction in a murine model. Our data indicate that the use of HDV, in combination with clinically approved TNFα immunomodulation, may represent an approach for improving the therapeutic index of Ad gene therapy for human clinical trials.

AB - Understanding the determinants of the host innate immune response to systemic administration of adenoviral (Ad) vectors is critical for clinical gene therapy. Acute toxicity occurs within minutes to hours after vector administration and is characterized by activation of innate immune responses. Our data indicate that in mice, indicators of vector toxicity include elevations of cytokine levels, liver transaminase levels and thrombocytopenia. To discern potential targets for blunting this host response, we evaluated genetic factors in the host response to systemically administered first-generation Ad vectors (FGV) and helper-dependent Ad vectors (HDV) containing β-galactosidase expression cassettes. A preliminary screen for modulation of vector-induced thrombocytopenia revealed no role for interferon-γ, mast cells or perforin. However, vector-induced thrombocytopenia and interleukin 6 (IL-6) expression are less evident in tumor necrosis factor alpha (TNFα)-deficient mice. Moreover, we also demonstrated that TNFα blockade via antibody or huTNFR:Fc pretreatment attenuates both thrombocytopenia (>40% increase in platelet count) and IL-6 expression (>80% reduction) without affecting interleukin 12, liver enzymes, hematological indices or vector transduction in a murine model. Our data indicate that the use of HDV, in combination with clinically approved TNFα immunomodulation, may represent an approach for improving the therapeutic index of Ad gene therapy for human clinical trials.

KW - Enbrel

KW - Helper-dependent

KW - Innate immune response

KW - Thrombocytopenia

KW - TNFalpha

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=33747611692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747611692&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302792

DO - 10.1038/sj.gt.3302792

M3 - Article

VL - 13

SP - 1272

EP - 1280

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 17

ER -